We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.00 | 7.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 6.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 31/12/2024 | 08:00 | UK RNS | London Stock Exchange Notice Cancellation - Argent Biopharma Limited |
| 16/12/2024 | 08:13 | UK RNS | Argent Biopharma Limited Additional Information for Shareholders |
| 29/11/2024 | 11:52 | ALNC |  Argent BioPharma to delist from LSE; hints at future dual US listing |
| 29/11/2024 | 07:00 | UK RNS | Argent Biopharma Limited ASX & LSE Listing Update |
| 28/11/2024 | 09:09 | UK RNS | Argent Biopharma Limited Result of AGM |
| 31/10/2024 | 07:00 | UK RNS | Argent Biopharma Limited September 2024 Quarterly Report |
| 25/10/2024 | 06:13 | UK RNS | Argent Biopharma Limited Dispatch of Annual General Meeting Documents |
| 24/10/2024 | 06:24 | UK RNS | Argent Biopharma Limited Placing to Raise A$200,000 |
| 15/10/2024 | 07:56 | UK RNS | Argent Biopharma Limited Holding(s) in Company |
| 15/10/2024 | 07:54 | UK RNS | Argent Biopharma Limited Director/PDMR Shareholding |
Argent Biopharma (RGT) Share Charts1 Year Argent Biopharma Chart |
|
1 Month Argent Biopharma Chart |
Intraday Argent Biopharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/12/2024 | 09:26 | RGT - To appear in February Medical Journal - Could Easily Double | 92 |
| 29/4/2016 | 17:06 | Regen Regenerated | 22 |
| 13/1/2015 | 18:20 | Does anyone have any new news on RGT? | 10 |
| 20/12/2014 | 08:33 | Regen Therapeutics Charts + News | 57,911 |
| 19/12/2014 | 18:17 | Lomax Interview, $1b company in the making (RGT) Add Favourite | 35 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 29/11/2024 08:45 by tomboyb delisting - |
Posted at 03/10/2024 06:35 by kenbos Means nothing to me but it must to some with the price going up |
Posted at 22/8/2024 13:15 by pierre oreilly Well I did own them briefly - sold them for 75 quid in total once I noticed them yesterday in my account. Afaics, they were the remnants of several thousand quid invested in mxc a couple of years ago, and now called Argent. (Nothing at all to do with the old RGT ticker which has just been recycled). Effectively bust due to the stupid government not authorising cannabis general use in the NHS. |
Posted at 21/8/2024 22:16 by dr biotech You don’t own them. Another company floated and used the RGT ticker… |
Posted at 10/4/2024 15:49 by greedfear All I have to do now is to find my share certificates. :( |
Posted at 03/3/2016 08:20 by stenick For anyone interest, from Rgt accounts.Revenues from sales of ColostrininTM for the year to 31 December 2014 were £17,000 (2012 - £52,000). Administrative costs have come down from £179,000 last year to £95,000 in 2014. Overheads have again been kept to a minimum. It should also be noted that within this figure there are non-cash items of £80,000 compared with £155,000 in 2013. These charges represent depreciation of the filtration rig (£27,000), the amortisation of patents (£44,000) and the amortisation of goodwill (£9,000). As a result of these factors the loss for the period after tax amounted to £100,000 (2013 - £171,000). On the 17th May 2012 the Company drew down the last £40,000 of the £240,000 loan facility available from Alexander David Investments PLC. With interest this has now accrued to a debt of £322,000 as at 31 December 2014 and interest continues to accrue. Technically this convertible loan could now be called upon after 14th February 2014. As previously stated this loan was taken over by Tiziana Life Sciences Plc after their acquisition of Alexander David Investments Plc (“ADI”). Discussions with Tiziana management have clarified that they do not intend to call in this loan but would convert this loan to RGTL shares at an appropriate time. Sales are down from last year mainly as a result of an order not being placed by our US distributor during 2014, although an order was placed in early 2015. We are working with a new licensee in India to secure regulatory approval to distribute the product direct to consumers there. The application has been with the regulatory agency for some months and a decision is expected soon. Our USA licensee Metagenics introduced a Colostrinin combination product (CerivaTM) via the 'professional' channel in summer 2014. Active ingredient for this launch stock was the main source of RGTL revenue in 2013. Detailed information is unavailable from Metagenics to ascertain how well the product is being received in the marketplace but the fact that they have recently suggested that no more material will be required during the remainder of 2015 or during the early part of 2016 suggests that the product is not selling as well as was hoped. Having obtained regulatory approval to do so, Tagerr our distributor in Poland have now switched from distributing product made by Metagenics to tablets supplied by RGTL.These are being well received but obviously sales here are on a modest scale. Cost saving initiatives continue. The Company runs from a virtual office. Both Directors and consultants remain unpaid (since December 2012) and will continue to defer their remuneration/fees until there is funding/finance available. The Directors continue to explore various ways of financing and developing the company with its advisers and contacts in order to secure a viable future for the Company in the best interest of shareholders. This includes the outright sale of the Company to a buyer that has the resources to fully exploit the sales potential of Colostrinin. So far a serious potential buyer has not been identified. |
Posted at 17/3/2015 18:32 by impala391 Time has stood still for Rgt. |
Posted at 10/12/2014 19:14 by doorway so whats going on here then are rgt still alive,and when this delisted did anyone get their new certs as mine was in a nominee account |
Posted at 09/12/2014 07:37 by asmodeus "cognisure unavailable, and not sure whether it will be again" (from site above, suggested by Share Shark) |
Posted at 15/2/2011 12:27 by share_shark A point to remember with regards to JP Jenkins.At one time they operated as OFEX and if you had watched the action,on that market was very good with share price prices moving with the demand on there. They were taken over and now operate as JP Jenkins but in essence,nothing has changed. So before you all say goodbye,as RGT shareholders and hello as RGTnewco shareholders and not forgetting ADI shareholders,it may be worth considering your wishes on this BB,for selling your shares. Ie. "Genises. I wish to sell 500000 shares,if anyone is interested at ??." Then someone would notice( Maysun) and contact JPJenkins and agree such a sale. Today is the last Board meeting of RGT's board of directors so lets hope a few of these well touted deals are forthcoming. Good luck everyone and I hope that those of you who are going to attend RGTnewcos first shareholders meeting will take a camera with you and let the rest of us know,what the long,the short and small actually look like.I will look forward to that too.;-))) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
